Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$194.29 USD

194.29
3,606,158

-1.16 (-0.59%)

Updated Oct 4, 2024 03:59 PM ET

After-Market: $193.91 -0.38 (-0.20%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Derek Lewis headshot

Reap Monthly Income With This Combination of 3 Stocks

While most stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get paid monthly if they position themselves carefully. Who doesn't like payday?

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

Smart Beta ETF report for DHS

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

Style Box ETF report for DHS

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases

Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA

With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.

Pfizer (PFE) Eczema Drug Cibinqo Gets FDA Nod for Adolescents

The FDA approval for Pfizer's (PFE) Cibinqo to treat moderate-to-severe atopic dermatitis in adolescents was based on data from the phase III study, JADE TEEN.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO

AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.

Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales

AbbVie's Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates.

AbbVie (ABBV) Q4 Earnings Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?

AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Derek Lewis headshot

AbbVie Q4 Preview: What's in Store?

AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Beats Q4 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints

Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.

Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Stock Moves -0.43%: What You Should Know

AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day.